GASTROESOPHAGEAL CANCER

This early-phase study tests a new drug called BG-68501 in people with advanced solid tumors that have not responded to standard treatments. The drug targets a protein (CDK2) that helps cancer cells grow. The trial will check safety, find the right dose, and see if the drug shrin…

This phase 2 trial is testing whether adding the drug neratinib to a standard combination of chemotherapy, trastuzumab, and pembrolizumab can shrink tumors in people with HER2-positive gastroesophageal cancers. The study includes 8 participants and aims to measure how many respon…

This early-stage trial is testing whether amivantamab, a drug that targets specific proteins on cancer cells, can be given as a shot under the skin instead of through an IV. About 158 adults with advanced solid tumors (like lung or head and neck cancers) will receive different do…

This study tests whether giving immunotherapy drugs (nivolumab alone or with relatlimab) before standard chemoradiation is safe and feasible for people with operable stage II/III esophageal or gastroesophageal junction cancer. About 32 adults will receive the drugs, then chemorad…

This phase 3 trial compares a new drug, MK-2870, against standard treatments for people with advanced stomach, gastroesophageal junction, or esophageal cancer that has spread and not responded to prior therapies. About 450 participants will be randomly assigned to receive either …

This early-phase trial is testing a combination of two immunotherapy drugs, naptumomab estafenatox and durvalumab, in 120 people with advanced or metastatic solid tumors like pancreatic, ovarian, and lung cancer. The main goal is to find a safe dose and see how the body reacts. R…

This study aimed to see if the immunotherapy drugs nivolumab and ipilimumab could help people with colorectal or gastroesophageal cancer avoid or delay major surgery. It was designed for adults with stage I to III cancers. However, the trial was withdrawn by the sponsor before en…

This study aimed to test whether a person's own immune cells, modified in a lab to target specific cancer-related mutations (KRAS or TP53), could prevent advanced gastrointestinal cancers from coming back after standard treatment. Participants would have been randomly assigned to…

This study tests a program that lets cancer patients receive care at home while undergoing chemotherapy or radiation. It includes remote monitoring and home visits to reduce the need for hospital stays or emergency room visits. The goal is to see if this approach improves quality…

This study tests a program that provides remote nutrition counseling and uses a Fitbit to track activity and diet for people with gastroesophageal cancer. Participants log their food intake and meet with a dietitian via video calls. The goal is to see if this approach is practica…

This early-phase study tests whether adding targeted radiation to immunotherapy drugs (nivolumab with or without relatlimab) is safe and can boost the immune system's attack on advanced stomach or esophageal cancer. About 21 adults with limited metastatic disease will receive rad…

This observational study collects blood and tumor tissue samples from people with gastroesophageal cancer to study genetic changes that may cause resistance to immunotherapy. It does not involve any treatment or experimental drugs. The goal is to identify new targets for future i…

This study looks for early signs of heart damage in people getting radiation therapy for lung or esophageal cancer. Researchers use heart scans and blood tests to see if changes happen during or shortly after treatment. The goal is to find patients at risk and help make future ca…